03:51 PM EST - ProMetic Life Sciences Inc. : announced today that it had a successful Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture. The Pre-IND meeting focused on ProMetic's proprietary Plasma Protein Purification manufacturing process as well as the clinical and regulatory pathway for this specific plasma-derived therapeutic. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.06 at $1.29.
